Signals, Powered By EquityPandit
Natco Pharma has got the Drugs Controller General of India’s approval to launch generic version of Gilead Sciences’ hepatitis C treatment drug in India.
Natco Pharma said in a BSE filing that “The company has received approval for the generic version of ledipasvir + sofosbuvir combination from Drugs Controller General (India)”.
It further said that Natco Pharma is planning to launch this combination drug immediately under its brand name Hepcinat LP and through its strategic partners in India.
